Peripheral Neuropathic Pain - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: P7040DD45CDEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Peripheral Neuropathic Pain - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Peripheral Neuropathic Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Peripheral Neuropathic Pain Understanding

The DelveInsight Peripheral Neuropathic Pain epidemiology report gives a thorough understanding of the Peripheral Neuropathic Pain by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Peripheral Neuropathic Pain in the US, Europe, and Japan. The report covers the detailed information of the Peripheral Neuropathic Pain epidemiology scenario in seven major countries (US, EU5, and Japan).

Peripheral Neuropathic Pain Epidemiology Perspective by DelveInsight

The Peripheral Neuropathic Pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Peripheral Neuropathic Pain epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Peripheral Neuropathic Pain epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Peripheral Neuropathic Pain Detailed Epidemiology Segmentation

The Peripheral Neuropathic Pain epidemiology covered in the report provides historical as well as forecasted Peripheral Neuropathic Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Peripheral Neuropathic Pain report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Peripheral Neuropathic Pain report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Peripheral Neuropathic Pain Epidemiology Report and Model provide an overview of the global trends of Peripheral Neuropathic Pain in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Peripheral Neuropathic Pain in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Peripheral Neuropathic Pain
• The report provides the segmentation of the Peripheral Neuropathic Pain epidemiology

Report Highlights

• 11-year Forecast of Peripheral Neuropathic Pain epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Peripheral Neuropathic Pain
• Cases of Peripheral Neuropathic Pain by Mutation Types
• Peripheral Neuropathic Pain Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Peripheral Neuropathic Pain?
• What are the key findings pertaining to the Peripheral Neuropathic Pain epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Peripheral Neuropathic Pain across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Peripheral Neuropathic Pain?
• What are the currently available treatments of Peripheral Neuropathic Pain?

Reasons to buy

The Peripheral Neuropathic Pain Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Peripheral Neuropathic Pain market
• Quantify patient populations in the global Peripheral Neuropathic Pain market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Peripheral Neuropathic Pain therapeutics in each of the markets covered
• Understand the magnitude of Peripheral Neuropathic Pain population by its epidemiology
• The Peripheral Neuropathic Pain Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF PERIPHERAL NEUROPATHIC PAIN

3. PERIPHERAL NEUROPATHIC PAIN: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Peripheral Neuropathic Pain Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Peripheral Neuropathic Pain Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Peripheral Neuropathic Pain Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Peripheral Neuropathic Pain Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Peripheral Neuropathic Pain Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Peripheral Neuropathic Pain Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Peripheral Neuropathic Pain Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Peripheral Neuropathic Pain Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Peripheral Neuropathic Pain Treatment and Management
6.2. Peripheral Neuropathic Pain Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Peripheral Neuropathic Pain Epidemiology in 7MM (2019-2032)
Table 2: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Peripheral Neuropathic Pain Epidemiology in the United States (2019-2032)
Table 4: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Peripheral Neuropathic Pain Epidemiology in Germany (2019-2032)
Table 6: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Peripheral Neuropathic Pain Epidemiology in France (2019-2032)
Table 8: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Peripheral Neuropathic Pain Epidemiology in Italy (2019-2032)
Table 10: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Peripheral Neuropathic Pain Epidemiology in Spain (2019-2032)
Table 12: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Peripheral Neuropathic Pain Epidemiology in the United Kingdom (2019-2032)
Table 14: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Peripheral Neuropathic Pain Epidemiology in Japan (2019-2032)
Table 16: Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Peripheral Neuropathic Pain Epidemiology in 7MM (2019-2032)
Figure 2 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Peripheral Neuropathic Pain Epidemiology in the United States (2019-2032)
Figure 4 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Peripheral Neuropathic Pain Epidemiology in Germany (2019-2032)
Figure 6 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Peripheral Neuropathic Pain Epidemiology in France (2019-2032)
Figure 8 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Peripheral Neuropathic Pain Epidemiology in Italy (2019-2032)
Figure 10 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Peripheral Neuropathic Pain Epidemiology in Spain (2019-2032)
Figure 12 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Peripheral Neuropathic Pain Epidemiology in the United Kingdom (2019-2032)
Figure 14 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Peripheral Neuropathic Pain Epidemiology in Japan (2019-2032)
Figure 16 Peripheral Neuropathic Pain Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report